Type I IFN would promote the production of cytokines and chemokines to modulate antigen presentation function of TAMs and tumor-antigen-specific CD8+ T cells activation and differentiation to produce powerful anti-tumor immune effects. The gene discussed is CD8A; the disease is neoplasm.